The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial.

Arnaud PagèsStéphanie FoulonZhaomin ZouLudovic LacroixFrançois LemareThierry de BaèreChristophe MassardJean-Charles SoriaJulia Bonastre

Published in: Genetics in medicine : official journal of the American College of Medical Genetics (2016)

This prospective cost analysis showed that molecular diagnosis accounts for only 6% of the cost of molecular-guided therapy per patient. The costs of drugs and hospitalizations are the main cost drivers.Genet Med advance online publication 01 December 2016.

Keyphrases

clinical trial
stem cells
healthcare
social media
phase iii
mesenchymal stem cells
open label
smoking cessation